4.8 Article

RCC2 is a novel p53 target in suppressing metastasis

Journal

ONCOGENE
Volume 37, Issue 1, Pages 8-17

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2017.306

Keywords

-

Funding

  1. National Natural Science Foundation of China [81430056, 31420103905, 81301801, 81621063, 31270769]
  2. National Key Research and Development Program of China [2016YFA0500302]
  3. Beijing Natural Science Foundation [7161007]
  4. Lam Chung Nin Foundation for Systems Biomedicine

Ask authors/readers for more resources

RCC2 (also known as TD60) is a highly conserved protein involved in prognosis in colorectal cancer. However, its relationship with tumor development is less understood. Here we demonstrate a signaling pathway defining regulation of RCC2 and its functions in tumor progression. We report that p53 is a transcriptional regulator of RCC2 that acts through its binding to a palindromic motif in the RCC2 promoter. RCC2 physically interacts and deactivates a small GTPase Rac1 that is known to be involved in metastasis. We solved a high-resolution crystal structure of RCC2 and revealed one RCC1-like domain with a unique beta-hairpin that is requisite for RCC2 interaction with Rac1. p53 or RCC2 deficiency leads to activation of Rac1 and deterioration of extracellular matrix sensing (haptotaxis) of surface-bound gradients. Ectopic expression of RCC2 restores directional migration in p53-null cells. Our results demonstrate that p53 and RCC2 signaling is important for regulation of cell migration and suppression of metastasis. We propose that the p53/RCC2/Rac1 axis is a potential target for cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available